Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine

Business Wire May 1, 2019

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

Business Wire April 26, 2019

Celgene Reports First Quarter 2019 Operating and Financial Results

Business Wire April 25, 2019

Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes

Business Wire April 17, 2019

Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb

Business Wire April 12, 2019

Celgene obtient des avis favorables du CHMP pour des associations triples de traitements à base de REVLIMID® et IMNOVID® pour les patients atteints de myélome multiple

Business Wire April 5, 2019

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

Business Wire April 5, 2019

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Benzinga.com  April 3, 2019

Option-trading opportunities on Bank of America Corp., BlackBerry Ltd., Citigroup Inc., Celgene Corp., and The Walt Disney Co.

PR Newswire April 1, 2019

62 Biggest Movers From Friday

Benzinga.com  April 1, 2019

Celgene Settles U.S. REVLIMID® Patent Litigation with Alvogen

Business Wire March 29, 2019

Option-trading opportunities on BB&T Corp., Celgene Corp., Canada Goose Inc., Kroger Co., and PepsiCo Inc.

PR Newswire March 29, 2019

Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma

Business Wire March 29, 2019

Yields In Focus Again As 10-Year Falls Below 2.4%; Homebuilder Earnings Digested

Benzinga.com  March 27, 2019

The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Benzinga.com  March 26, 2019

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Business Wire March 25, 2019

Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials

Business Wire March 25, 2019

Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

Business Wire March 12, 2019

Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

Business Wire March 11, 2019

U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

Business Wire March 5, 2019